Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
During a two year prospective study onpatients from department's hospitals and centralized by the pneumology department Nantes CH,all respiratory clinical samples will be cultivated for Aspergillus isolation (2900Aspergillusisolates) as standard care. The azole susceptibility pattern of isolates will be determined to itraconazole, voriconazole by subculture on azole- enriched medium at 35°c as primary screen and resistance confirmed by EUCAST Reference metho.In parallel, the relevance of detecting resistance (TR34 and TR46) directly in culture-negative BAL respiratory samples by a qPCR method will be studied in an attempt to reach a greater exhaustiveness of the resistance phenomeno. In case of azole-resistant isolate,patient data such as the underlying disease,date and site of Aspergillus isolation,disease classification,previous azole drug exposure,and home and work geographic allocation,occupation of the patient will be collecte. For all other aspergillus occurrences, underlying disease, previous azole drug exposure,home and work location of the patient will be collected in an attempt to identify risk factor.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Group control : patient without resistance | control patients with susceptible Aspergillus. |
| |
| Group resistant : patient without resistance | Cases are patients with resistant Aspergillus |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| No intervention | Other | No intervention excepted data collection |
|
| Measure | Description | Time Frame |
|---|---|---|
| Environmental risk factors | Identify the "macro" environmental risk factors for acquiring azole-resistant aspergillus. | 24 months |
| Measure | Description | Time Frame |
|---|---|---|
| Describe the management and evolution of resistant | Clinical information from each additional patient visit and presence or absence of resistant Aspergillus in home samples. | 48 months |
| Risk factors |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Prospective inclusion of patients sampled as part of their care in a pneumology department (Nantes University Hospital or CHD Vendée) who are carriers of aspergillus. Patients will be contacted by email or paper mail if a strain is isolated.
Only patients with resistant strains and susceptible patients matched to resistant strains for this study will also receive a home visit from the CMEI (except for patients living in institutions).
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| François-Xavier Blanc, PUPH | Contact | 0240165710 | xavier.blanc@chu-nantes.fr |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| CHU de Nantes | Nantes | 44093 | France |
|
Not provided
Not provided
Not provided
Not provided
Identify individual risk factors linked to the immediate environment in the patient's home, drug management, between cases and matched controls, etc..
| 48 months |